Ueda Taeko
   Department   School of Medicine  Obstetrics and Gynecology, Clinical Medical Sciences
Article types journal article
Language English
Peer review Peer reviewed
Title A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Journal Formal name:Anticancer research
Abbreviation:Anticancer Res
ISSN code:17917530/02507005
Domestic / ForeginForegin
Volume, Issue, Page 31(7),2461-2465頁
Author and coauthor Tsujioka Hiroshi, Fukami Tatsuya, Yotsumoto Fusanori, Ueda Taeko, Hikita Shoko, Takahashi Yoko, Kondo Haruhiko, Kuroki Masahide, Miyamoto Shingo
Publication date 2011/07
Summary AIM:Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a promising target for cancer therapy. We have already started a phase I study of CRM197, a specific HB-EGF inhibitor, for advanced ovarian cancer. In this study, we evaluated possible clinical adaptations of CRM197 in combination with conventional chemotherapeutic agents.MATERIALS AND METHODS:CRM197, bevacizumab, and paclitaxel were intraperitoneally administered either alone or in combination with mice xenografted with ES2 human ovarian cancer cells. The tumor volumes and microvessel densities (MVD) were determined.RESULTS:Enhanced antitumor effects were observed when paclitaxel was used in combination with bevacizumab or CRM197. The antitumor effect of paclitaxel/CRM197 was significantly higher than that of paclitaxel/bevacizumab. The tumor MVD of mice treated with paclitaxel/CRM197 was significantly lower than that of mice treated with paclitaxel/bevacizumab.CONCLUSION:CRM197 in combination with paclitaxel significantly blocked tumor formation and angiogenesis. These results suggest that paclitaxel is a suitable candidate for CRM197 combination therapy.
PMID 21873160